Literature DB >> 1396868

Reduced peripheral and coronary vasomotion in systemic hypertension.

M Leschke1, F C Schoebel, M Vogt, M Heintzen, M Kelm, W Motz, B E Strauer.   

Abstract

In 53 patients with a history of arterial hypertension and 16 normotensive control subjects, coronary blood flow reserve by means of the argon method, and peripheral vascular flow reserve by means of venous occlusion plethysmography, were studied. The coronary flow reserve, expressed as the ratio of coronary vascular resistance under resting conditions to the minimal coronary vascular resistance after the administration of dipyridamole, was 4.34 +/- 0.89 in the normotensive group and 2.18 +/- 0.60 in the hypertensive group. There was no significant difference in forearm peak flow after 3 min of arterial occlusion between normotensive and hypertensive patients, while the peripheral minimal vascular resistance was significantly higher in hypertensive patients (8.8 +/- 3.8 mmHg x ml.min-1 x 100 ml-1 tissue) as compared to normotensive subjects (6.37 +/- 2.37 mmHg x ml.min-1 x 100 ml-1 tissue). Parallel to the reduction in coronary reserve, the peripheral flow reserve, expressed as the ratio of peripheral resting vascular resistance to peripheral minimal vascular resistance after 3 min of arterial occlusion, was significantly lower (P less than 0.01) in hypertensive subjects (3.85 +/- 2.28) as compared to normotensive subjects (5.31 +/- 1.72). These data suggest that in hypertensives an impaired vasodilator reserve of both coronary and peripheral microcirculation exists.

Entities:  

Mesh:

Year:  1992        PMID: 1396868     DOI: 10.1093/eurheartj/13.suppl_d.96

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  1 in total

Review 1.  Differences in coronary blood flow in aortic regurgitation and systemic arterial hypertension have implications for diastolic blood pressure targets: a systematic review and meta-analysis.

Authors:  Simon W Rabkin
Journal:  Clin Cardiol       Date:  2013-08-27       Impact factor: 2.882

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.